Mia's Feed
Medical News & Research

Reunion Hospital Calls for Additional Medical Staff to Combat Chikungunya Outbreak

Reunion Hospital Calls for Additional Medical Staff to Combat Chikungunya Outbreak

Share this article

2 min read

The healthcare authorities on Reunion Island, a French territory in the Indian Ocean, are experiencing a significant strain due to a recent chikungunya virus outbreak. Lionel Calenge, the head of the island's hospital services, issued a plea for more medical personnel to help manage the rising number of cases. According to Calenge, the hospitals are operating at full capacity, with the emergency wards treating between 30 and 40 chikungunya patients daily. Since the beginning of 2025, there have been over 580 hospitalizations related to the virus, including cases involving newborns. The outbreak has also incapacitated a large portion of the medical staff, with around 540 personnel unable to work after contracting the disease. Although an initial decrease in the epidemic's severity was observed in early April, the situation remains critical, prompting the hospitals to delay elective surgeries and recall staff on leave. Calenge emphasized the urgent need for six additional doctors to bolster the healthcare response amid the ongoing epidemic. This outbreak coincides with a visit by French President Emmanuel Macron to Reunion Island, highlighting the importance of prompt medical intervention and support. The situation continues to require extensive medical resources and community efforts to control the spread of chikungunya on the island.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Promising Results from Antibody-Drug Conjugate in Treating Rare Blood Cancer

A novel antibody-drug conjugate shows high response rates and safety in treating the rare and aggressive blood cancer BPDCN, potentially offering a new standard of care.

FDA Approves Targeted Therapy for Rare and Aggressive Blood Cancer Following Promising Clinical Trial Results

A groundbreaking clinical trial has led to FDA approval of pemigatinib for treating a rare and deadly blood cancer, offering new hope through targeted therapy and transplantation options.

New Insights into Mitochondrial Dysfunction's Role in Alzheimer’s Disease Progression and Therapy

Recent Mayo Clinic research highlights mitochondrial complex I dysfunction as a key factor in Alzheimer's disease, opening new paths for early intervention and personalized treatment strategies.

Long-Term Risks for Childhood Cancer Survivors During the COVID-19 Pandemic

A groundbreaking study reveals that adults who survived childhood cancer are at greater risk of severe COVID-19, emphasizing the need for targeted protective measures for this vulnerable group.